Artificial intelligence is becoming more deeply embedded across the pharmaceutical industry, and that makes governance a matter of strategy rather than administration. The underlying investment relevance is straightforward. As AI takes on a larger role in areas such as development, decision support and patient-related activity, the companies that can show discipline around oversight are likely to be better placed to manage regulatory exposure, operational risk and stakeholder confidence.
At its core, AI governance is about the policies, controls and processes that shape how AI is developed, introduced and managed. In a sector where patient safety, privacy and compliance sit close to the centre of every major decision, that structure matters. Without it, the use of AI can create avoidable problems, whether through poor-quality outputs, weak accountability or decisions that are difficult to explain.
AI systems reflect the data used to train them, and in healthcare that can produce uneven outcomes if not properly addressed. Governance matters because it creates a process for testing, reviewing and correcting those distortions over time. If systems are seen as unreliable or unfair, management teams may face resistance from clinicians, patients and regulators, which can reduce the practical value of the underlying technology.
In pharma, black-box decision-making is rarely a comfortable position, particularly when external stakeholders need to understand how an output has been produced and whether it can be trusted. Governance supports transparency through documentation, defined standards and clearer visibility over data use and model behaviour.
Healthcare data is highly sensitive, and governance provides the framework for how that information is collected, stored and used. In practical terms, strong controls can help reduce the risk of breaches and reinforce confidence that data is being handled appropriately. That has obvious implications for reputation, but also for continuity. Businesses that fall short on privacy may find innovation delayed by remediation work, scrutiny or internal caution.
Taken together, these issues feed into a broader question of trust. In healthcare, adoption depends not only on what technology can do, but on whether people believe it should be used. Governance helps build that confidence by showing that oversight, accountability and ethical judgement are present alongside technical capability.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
